Skip to main content
. Author manuscript; available in PMC: 2025 Apr 10.
Published in final edited form as: Ann Surg Oncol. 2019 Jul 16;26(12):4108–4116. doi: 10.1245/s10434-019-07602-6

TABLE 2.

Odds for completion of adjuvant chemotherapy after upfront surgical resection for pancreatic adenocarcinoma among patients who received at least one dose of adjuvant chemotherapy

OR 95% CI
Diagnosis period
 2004–2008 1.00 Reference
 2009–2013 1.05 0.75 1.45
Age categories (years)
 66–69 1.00 Reference
 70–74 1.20 0.79 1.82
 75–79 0.97 0.62 1.51
 80–84 0.73 0.42 1.26
 ≥ 85 0.43 0.15 1.22
Gender
 Male 1.00 Reference
 Female 0.84 0.61 1.16
Race
Non-Hispanic white 1.00 Reference
 Black 0.77 0.36 1.61
 Other 0.61 0.35 1.06
Surgical procedure
Whipple 1.00 Reference
 Total pancreatectomy 1.35 0.87 2.09
 Other 0.95 0.60 1.51
Tumor size (cm)
 <2 1.00 Reference
 ≥ 2 1.43 0.82 2.49
T stage
1 and 2 1.00 Reference
 3 1.12 0.74 1.69
 4 0.64 0.15 2.73
CCI
 0 1.00 Reference
 1 0.82 0.57 1.2
≥ 2 0.57 0.36 0.91
Nodal metastases
None 1.00 Reference
Yes 1.67 1.14 2.46
 No nodes evaluated 1.75 0.78 3.93
Lymph nodes evaluated
 < 15 1.00 Reference
 15+ 1.08 0.77 1.51
NCI-designated cancer center
 No 1.00 Reference
Yes 4.25 2.68 6.76

Bold type designates statistical significance

OR odds ratio, CI confidence interval, CCI Charlson Comorbidity Index, NCI National Cancer Institute